Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 2Efficacy & side effects

1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (50.0%)

Phase 21 (50.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completed

Biological Variables Affecting CD34+ Peripheral Cells Collection Efficiency

NCT06308133

completedphase_1

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474

completedphase_2

Plerixafor for Stem Cell Mobilization in Normal Donors

NCT01818284

Clinical Trials (3)

Showing 3 of 3 trials

NCT06308133

Biological Variables Affecting CD34+ Peripheral Cells Collection Efficiency

Completed

NCT01176474Phase 1

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Completed

NCT01818284Phase 2

Plerixafor for Stem Cell Mobilization in Normal Donors

Completed

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3